UBS Group AG Grows Stock Holdings in Roivant Sciences Ltd. $ROIV

Key Points

• UBS Group AG increased its stake in Roivant Sciences by 570% in Q4 to 18,390,792 shares (about 2.64% of the company), valued at roughly $399.08 million.
• Insiders have been net sellers: CEO Eric Venker sold 200,000 shares (~$5.92M) and Director Melissa Epperly sold 41,861 shares, with insiders disposing of 5,085,398 shares worth about $139.2 million in the past 90 days.
• Analyst sentiment is mixed but tilted positive — the stock has a consensus rating of "Moderate Buy" with a consensus target of $30.55, while firms like Piper Sandler and Citigroup raised targets to $40 and $35, respectively.

UBS Group AG raised its stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 570.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,390,792 shares of the company's stock after buying an additional 15,645,836 shares during the period. UBS Group AG owned about 2.64% of Roivant Sciences worth $399,080,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. Jones Financial Companies Lllp boosted its position in Roivant Sciences by 226.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company's stock valued at $25,000 after buying an additional 1,148 shares during the period. Allworth Financial LP boosted its position in Roivant Sciences by 48.1% in the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company's stock valued at $27,000 after buying an additional 583 shares during the period. Bessemer Group Inc. boosted its position in Roivant Sciences by 41.5% in the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company's stock valued at $28,000 after buying an additional 543 shares during the period. Farther Finance Advisors LLC boosted its position in Roivant Sciences by 59.6% in the 4th quarter. Farther Finance Advisors LLC now owns 3,600 shares of the company's stock valued at $78,000 after buying an additional 1,345 shares during the period. Finally, Aster Capital Management DIFC Ltd boosted its position in Roivant Sciences by 75.8% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 4,405 shares of the company's stock valued at $67,000 after buying an additional 1,900 shares during the period. 64.76% of the stock is owned by hedge funds and other institutional investors.

Roivant Sciences Stock Performance

NASDAQ:ROIV opened at $27.85 on Tuesday. Roivant Sciences Ltd. has a one year low of $10.58 and a one year high of $30.33. The firm has a market cap of $19.93 billion, a P/E ratio of -23.80 and a beta of 1.20. The firm has a 50-day simple moving average of $28.26 and a 200-day simple moving average of $23.76.

Analysts Set New Price Targets

Several research firms have issued reports on ROIV. Weiss Ratings cut shares of Roivant Sciences from a "hold (c-)" rating to a "sell (d)" rating in a research report on Monday, February 9th. Jefferies Financial Group reissued a "buy" rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. Piper Sandler boosted their price objective on shares of Roivant Sciences from $22.00 to $40.00 and gave the company an "overweight" rating in a research report on Thursday, April 16th. Guggenheim boosted their price objective on shares of Roivant Sciences from $28.00 to $30.00 and gave the company a "buy" rating in a research report on Monday, February 9th. Finally, Citigroup boosted their price objective on shares of Roivant Sciences from $26.00 to $35.00 and gave the company a "buy" rating in a research report on Tuesday, February 10th. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $30.55.

Insiders Place Their Bets

In other news, Director Melissa B. Epperly sold 41,861 shares of the business's stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $28.68, for a total value of $1,200,573.48. Following the completion of the sale, the director owned 15,804 shares in the company, valued at approximately $453,258.72. The trade was a 72.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Eric Venker sold 200,000 shares of the business's stock in a transaction dated Monday, April 20th. The shares were sold at an average price of $29.59, for a total transaction of $5,918,000.00. Following the completion of the sale, the chief executive officer owned 1,647,546 shares of the company's stock, valued at approximately $48,750,886.14. This represents a 10.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 5,085,398 shares of company stock worth $139,215,946. 10.80% of the stock is owned by corporate insiders.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

Want to see what other hedge funds are holding ROIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.